Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Alterations in peripheral and central indices of serotonin (5-hydroxytryptamine, 5-HT) production, storage and signaling have long been associated with autism. The 5-HT transporter gene (HTT, SERT, SLC6A4) has received considerable attention as a potential risk locus for autism-spectrum disorders, as well as disorders with overlapping symptoms, including obsessive-compulsive disorder (OCD). Here, we review our efforts to characterize rare, nonsynonymous polymorphisms in SERT derived from multiplex pedigrees carrying diagnoses of autism and OCD and present the initial stages of our effort to model one of these variants, Gly56Ala, in vivo. We generated a targeting vector to produce the Gly56Ala substitution in the Slc6a4 locus by homologous recombination. Following removal of a neomycin resistance selection cassette, animals exhibiting germline transmission of the Ala56 variant were bred to establish a breeding colony on a 129S6 background, suitable for initial evaluation of biochemical, physiological and behavioral alterations relative to SERT Gly56 (wildtype) animals. SERT Ala56 mice were achieved and exhibit a normal pattern of transmission. The initial growth and gross morphology of these animals is comparable to wildtype littermate controls. The SERT Ala56 variant can be propagated in 129S6 mice without apparent disruption of fertility and growth. We discuss both the opportunities and challenges that await the physiological/behavioral analysis of Gly56Ala transgenic mice, with particular reference to modeling autism-associated traits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 1×
“More consistent data supports the use of risperidone [44, 45], an atypical antipsychotic with antagonism at multiple monoamine receptors, including the 5-HT2A receptor.”
BackgroundMoy, S. S., Nadler, J. J., Perez, A., Barbaro, R. P., Johns, J. M., Magnuson, T. R., Piven, J., & Crawley, J. N. (2004) · Genes, Brain and Behavior · doi:10.1111/j.1601-1848.2004.00076.x · Cited by 1,522 · cited 1×
“Will the SERT Ala56 mice show alterations in social behavior [89]? Will they show repetitive behavior, perseverative exploration, or deficits in reversal learning, paralleling the association of SERT Ala56 with rigid-compulsive behavior [90]? Will they show increased sensory sensitivity, paralleling the association wi…”
BackgroundStudies on 5-hydroxyindole metabolism in autistic and other mentally retarded children
Schain, R. J., & Freedman, D. X. (1961) · The Journal of Pediatrics · doi:10.1016/s0022-3476(61)80261-8 · Cited by 579 · cited 1×
“Freedman in 1961 [1], well before 5-HT was fully accepted as a neurotransmitter [2].”
BackgroundMouse Behavioral Assays Relevant to the Symptoms of Autism*
Crawley, J. N. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00096.x · Cited by 541 · cited 1×
“Some of these questions correspond to establishing face validity for behavioral traits that map onto autism symptoms (reviewed in [88]).”
BackgroundTargeting the murine serotonin transporter: insights into human neurobiology
Murphy, D. L., & Lesch, K.-P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2284 · Cited by 478
A Genomewide Screen for Autism: Strong Evidence for Linkage to Chromosomes 2q, 7q, and 16p
(2001) · The American Journal of Human Genetics · doi:10.1086/323264 · Cited by 453
Sutcliffe, J. S., Delahanty, R. J., Prasad, H. C., McCauley, J. L., Han, Q., Jiang, L., Li, C., Folstein, S. E., & Blakely, R. D. (2005) · The American Journal of Human Genetics · doi:10.1086/432648 · Cited by 392 · cited 11×
“Phe465Leu [ 49 ] Transmembrane domain ~70% increase in 5-HT uptake; increased cell surface expression [79] Leu550Val [49] Transmembrane domain ~70% increase in 5-HT uptake; increased cell surface expression [79]”
BackgroundInfluentialSelf-citationEffects of tryptophan depletion in drug-free adults with autistic disorder
McDougle, C. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830110029004 · Cited by 301
Social approach in genetically engineered mouse lines relevant to autism
Moy, S. S., Nadler, J. J., Young, N. B., Nonneman, R. J., Grossman, A. W., Murphy, D. L., D’Ercole, A. J., Crawley, J. N., Magnuson, T. R., & Lauder, J. M. (2009) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2008.00452.x · Cited by 246 · cited 1×
“Despite seeing decreased platelet 5-HT levels, the opposite of what is observed in the hyperserotonemia of autism, these mice also show decreased sociability in the Crawley test [83].”
BackgroundMulder, E. J., Anderson, G. M., Kema, I. P., de Bildt, A., van Lang, N. D., den Boer, J. A., & Minderaa, R. B. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200404000-00016 · Cited by 199
Cited by
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Petra, A. I., Panagiotidou, S., Hatziagelaki, E., Stewart, J. M., Conti, P., & Theoharides, T. C. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.04.002 · Cited by 592
Veenstra-VanderWeele, J., Muller, C. L., Iwamoto, H., Sauer, J. E., Owens, W. A., Shah, C. R., Cohen, J., Mannangatti, P., Jessen, T., Thompson, B. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112345109 · Cited by 333
“SERT Ala56 knock-in mice were constructed as previously described (22).”
BackgroundMethodInfluentialSelf-citationSLC6 transporters: Structure, function, regulation, disease association and therapeutics
Pramod, A. B., Foster, J., Carvelli, L., & Henry, L. K. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.002 · Cited by 319
Margolis, K. G., Li, Z., Stevanovic, K., Saurman, V., Israelyan, N., Anderson, G. M., Snyder, I., Veenstra-VanderWeele, J., Blakely, R. D., & Gershon, M. D. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84877 · Cited by 139
Self-citation
Metadata
- Authors
- Veenstra-VanderWeele, J., Jessen, T. N., Thompson, B. J., Carter, M., Prasad, H. C., Steiner, J. A., Sutcliffe, J. S., & Blakely, R. D.
- Venue
- Journal of Neurodevelopmental Disorders
- Published
- 2009-06
- Volume
- 1
- Issue
- 2
- Pages
- 158-171
- ISSN
- 1866-1947 (ISSN-L)
- 1866-1955
- OpenAlex
- W2118507010
- Cited by
- 43
- References
- 17
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse. https://app.cochat.ai/papers/10.1007/s11689-009-9020-0
- The paper
- Veenstra-VanderWeele, J., Jessen, T. N., Thompson, B. J., Carter, M., Prasad, H. C., Steiner, J. A., Sutcliffe, J. S., & Blakely, R. D. (2009). Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse. Journal of Neurodevelopmental Disorders. https://doi.org/10.1007/s11689-009-9020-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.